REMARKS

The foregoing Preliminary Amendment is requested in order to delete the multiple dependent claims and avoid paying the multiple dependent claims fee.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

Early action on the merits is respectfully requested.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By _____
William E. Player
Reg. No. 31,409

400 Seventh Street, N.W.
Washington, D.C. 20004-2201
(202) 638-6666

Atty. Docket: P67214US0
Date: November 5, 2001
WEP:jrc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

3. (amended) Use of the method according to claims 1 ~~or 2~~ for evaluating a treatment for Alzheimer's disease.

4. (amended) The method according to claim 1 ~~any of claims 1 to 3~~, wherein a level of nerve growth factor ≥ 4 pg/ml in said cerebrospinal fluid indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

6. (amended) The method according to claim 1 ~~any of claims 1 to 5~~, wherein said subject is a human.

7. (amended) The method according to claim 1 ~~any of claims 1 to 6~~, wherein nerve growth factor is detected using an immunoassay, bioassay and/or binding assay.

8. (amended) The method according to claim 1 ~~any of claims 1 to 7~~, further comprising comparing a level and/or an activity of nerve growth factor in said sample with a level and/or an activity in a series of samples taken from said subject over a period of time.

9. (amended) The method according to claim 1 ~~any of claims 1 to 8~~, wherein said subject receives a treatment prior to one or more of said sample gatherings.

10. (amended) The method according to claim 1 ~~any of claims 1 to 9~~, wherein said level and/or activity in said samples is determined before and after said treatment of said subject.

11. (amended) The method according to claim 1 ~~any of claims 1 to 10~~, further comprising:

determining a level, or an activity, or both said level and said activity, of a further neurotrophin in a sample taken from cerebrospinal fluid of said subject;

and comparing said level, or said activity, or both said level and said activity, to a reference value representing a known disease or health status;

wherein a varied level, or activity, or both said level and said activity, of said further neurotrophin in said cerebrospinal fluid from said subject relative to said reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

17. (amended) The kit according to claim 14 ~~any of claims 14 to 16~~ further comprising:

(a) at least one reagent which selectively detects a further neurotrophin; and

(b) instructions for diagnosing, or prognosing Alzheimer's disease, or determining increased risk of developing Alzheimer's disease by

(i) detecting a level, or an activity, or both said level and said activity, of said further neurotrophin in a sample taken from cerebrospinal fluid of said subject; and

(ii) diagnosing, or prognosing, or determining whether said subject is at increased risk of developing Alzheimer's disease, wherein a varied level or activity, or both said level and said activity, of said further neurotrophin compared to a reference value representing a known health status,

or a level, or an activity, or both said level and said activity, of said further neurotrophin similar or equal to a reference value representing a known disease status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

20. (amended) The kit according to claim 14 ~~any of claims 14 to 19~~ for use in monitoring a progression of Alzheimer's disease in a subject.

21. (amended) The kit according to claim 14 ~~any of claims 14 to 19~~ for use in monitoring the success or failure of a therapeutic treatment of a subject.